ClinicalTrials.gg
Status unknownNCT05317715EPODIUUpdated May 2, 2022

Evaluation of the Impact of an Oral and Practical Presentation of Intrauterine Devices by a Health Professional on Women's Opinion as a Possible Contraceptive Method

An interventional study of Group A, who will complete a questionnaire before receiving information about intrauterine devices and Group B who will answer a questionnaire after having the information about the intrauterine devices in Acceptance Processes, sponsored by Raincy Montfermeil Hospital Group. Status unknown at 1 site in France. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Raincy Montfermeil Hospital Group · Not applicable, Interventional, and Other

How we know

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Behavior with a site in France — 15 open to participants now, 15 under way, none of them phase 3. Behavior · France.

Planned enrollment
14th of 47
160 · median 100
Started
2022
with 4 others
No phase
45 of 69
14 open now
Registered
49th of 69
by date

Among the 69 studies in Behavior with a site in France, this one is the 14th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2022, is one of 45 with no phase, and was the 49th registered.

Behavior

1,579 studies on the registry are indexed under Behavior; 314 are open to participants now.

Browse Behavior studies →

Open to participants now

15 of the 69 studies in Behavior with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 177 Behavior studies recruiting now, 77 (44%) set no upper age limit and 72 (41%) stop at 75 or younger; 58 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Behavior with a site in France, or all of them as a file.
02

Study summary

Contraception among women in France has evolved considerably and has become a frequent reason for consultation in general practice in view of the growing shortage of gynaecologists practising in towns.

Intrauterine devices (IUDs) are the leading reversible contraceptive method used in the world, but only 20.7% of women in France were using them in 2010.

In practice, in France, use of the IUD is still "reserved" for older women or those who have already had children, despite medical recommendations.

In this study the investigator will investigate whether clear information about the mode of action and insertion/withdrawal of IUDs would dispel these misconceptions of patients.

Read the detailed description

Contraception among women in France has evolved considerably and has become a frequent reason for consultation in general practice in view of the growing shortage of gynaecologists practising in towns.

Intrauterine devices (IUDs) are the leading reversible contraceptive method used in the world, but only 20.7% of women in France were using them in 2010.

In practice in France, the use of IUDs is still "reserved" for older women or those who have already had children, despite medical recommendations. Indeed, there is a certain feeling of mistrust towards the IUD as a contraceptive method. Sometimes the patient's reasons for refusal were unclear or misconceptions and prejudices prevailed.

Various research studies and theses have identified the various obstacles to the use of the IUD as a contraceptive. Today it would be interesting to evaluate whether a short presentation of the IUD during a consultation would lead to a better acceptance of women to use it as a possible contraceptive method.

In this study the investigators will investigate whether clear information about the mode of action and insertion/removal of IUDs would dispel these misconceptions of patients.

03

Conditions studied

  • Acceptance Processes

Browse trials for

Keywords

  • Contraception
  • Intrauterine devices
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any woman aged 18 years and over who comes to a family planning centre
  • Having expressed her free and informed written consent
  • Affiliated to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Women under 18 years of age
  • Woman with an IUD
  • Woman who has had an IUD before
  • Woman whose reason for consultation of the day is the insertion of an IUD
  • Menopausal woman
  • Woman who is infertile for any reason
  • Illiterate woman or woman who does not read French
  • Refusal to participate in the protocol
  • Incapable of age.
  • Pregnant or breastfeeding women
  • Vulnerable persons and protected persons as provided for in the Public Health Code Public Health Code (articles L. 1121-5 to L.1121-8 and L.1122-1-2).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Other
    without device information

    this group of patients will complete a questionnaire before receiving information on contraceptive intrauterine devices (copper or hormonal)

    Other: Group A, who will complete a questionnaire before receiving information about intrauterine devices

  • Other
    with device information

    This group of patients will receive information about contraceptive intrauterine devices (copper or hormonal) before completing a questionnaire

    Other: Group B who will answer a questionnaire after having the information about the intrauterine devices

Interventions

  • OtherGroup A, who will complete a questionnaire before receiving information about intrauterine devices

    Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.

  • OtherGroup B who will answer a questionnaire after having the information about the intrauterine devices

    Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.

06

What researchers measure

Primary outcomes

  1. Rate of acceptance of the IUD as a possible contraceptive method

    measuring the acceptance rate of the intrauterine device as a potential contraceptive method

    Time frame: day 1

Secondary outcomes

  1. Basic knowledge of intrauterine devices

    verification of Basic knowledge of intrauterine devices

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
  • Le Raincy Montfermeil hospital
    Montfermeil, 93370, France
    Recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Aug 2022, 4 months after the start.

Of 745 non-industry interventional studies with no phase under Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 4 months is below that.

Counting every sponsor, half of 761 studies reached it within 13 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Apr 8, 2022
StartActual
Apr 14, 2022
Primary completionEst.
Aug 14, 2022
CompletionEst.
Oct 2022
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05317715
Lead sponsor
Raincy Montfermeil Hospital Group
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
Apr 14, 2022
Primary completion
Aug 14, 2022 (estimated)
Completion
Oct 2022 (estimated)
Last update
May 2, 2022

Study contacts

Jean GUILLEMINOT, MD
Contact
jean.guilleminot@ght-gpne.fr
01 41 70 81 19 ext. +33
Jean GUILLEMINOT, MD
principal investigator · Le Raincy Montfermeil hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion